Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay

JAMA. 2014 Jul 2;312(1):23-4. doi: 10.1001/jama.2014.6672.
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / economics*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / economics
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Centers for Medicare and Medicaid Services, U.S. / economics
  • Cost Control
  • Drug Approval
  • Drug Costs*
  • Drug Industry / economics
  • Humans
  • Macular Degeneration / drug therapy*
  • Medicare / economics*
  • Off-Label Use*
  • Ranibizumab
  • Receptors, Vascular Endothelial Growth Factor / economics
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / economics
  • Recombinant Fusion Proteins / therapeutic use
  • United States
  • United States Food and Drug Administration
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab